(Q39805134)

14 September 2017

1 reference

title

New experimental antimalarial drugs (English)

1 reference

14 September 2017

New Experimental Antimalarial Drugs (English)

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

15 April 2023

0 references

R. S. Rozman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A382797

15 April 2023

C. J. Canfield

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A382797

15 April 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=382797

15 April 2023

1 January 1979

1 reference

Advances in pharmacology and chemotherapy

14 September 2017

published in

1 reference

14 September 2017

volume

16

1 reference

14 September 2017

page(s)

1-43

1 reference

Enhancement of solubility of drug salts by hydrophilic counterions: properties of organic salts of an antimalarial drug

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

A phenanthrene methanol (WR 33063) for treatment of acute malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Pharmacology of new antimalarial drugs. Two quinolinemethanols

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Antimalarials. 7. 2,8-Bis(trifluoromethyl)-4-quinolinemethanols

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Pulmonary and cardiovascular effects of mefloquine methanesulfonate

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Treatment of falciparum malaria from Vietnam with a phenanthrene methanol (WR 33063) and a quinoline methanol (WR 30090).

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Optical isomers of aryl-2-piperidylmethanol antimalarial agents. Preparation, optical purity, and absolute stereochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Further side-chain modification of antimalarial phenanthrene amino alcohols

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Difference in antimalarial activity between certain amino alcohol diastereomers

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Prophylactic Activity of a Phenanthrene Methanol (WR 33063) and a Quinoline Methanol (WR 30090) in Human Malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Suppressive activity of mefloquine in sporozoite-induced human malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Antimalarial arylaminopropanols

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Evaluating new antimalarial drugs against trophozoite induced Plasmodium cynomolgi malaria in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Mefloquine, a clinically useful quinolinemethanol antimalarial which does not significantly bind to DNA

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Molecular structural effects involved in the interaction of quinolinemethanolamines with DNA. Implications for antimalarial action

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Plasmodium berghei: phase contrast and electron microscopical evidence that certain antimalarials can both inhibit and reverse pigment clumping caused by chloroquine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Mutagenic Studies of Folic Acid Antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Quantitation of the antimalarial agent, mefloquine, in blood, plasma, and urine using high-pressure liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

The treatment of malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Comparison of A 9-phenanthrene methanol (WR33063), a 4-quinoline methanol (wr30090), and quinine for falciparum malaria in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Sequential treatment with quinine and mefloquine or quinine and pyrimethamine-sulfadoxine for falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Preparation and antimalarial activity of some derivatives of 6-bromo-.alpha.-(di-n-heptylaminomethyl)-9-phenanthrenemethanol

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Biological screening in the U.S. Army antimalarial drug development program

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Antimalarials. 6. Synthesis, antimalarial activity, and configurations of racemic .alpha.-(2-piperidyl)-4-pyridinemethanols

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Antimalarials; alpha-alkyl and dialkylaminomethyl-2-phenyl-4-quinolinemethanols.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

A quinoline methanol (WR 30090) for treatment of acute malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Attempts to find new antimalarials; amino alcohols of the type=m=mCHOHCH2NR2 derived from 3-bromo-10-acetyl-phenanthrene.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Antimalarial phenathrene amino alcohols. 1. Fluorine-containing 3- and 6-substituted 9-phenanthrenemethanols

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Antimalarials. 7. Bis(trifluoromethyl)-.alpha.-(2-piperidyl)-4-quinolinemethanols

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Photolytic Degradation of α-[(Dibutylamino)methyl]-6,8-dichloro-2-(3′,4′-dichlorophenyl)-4-quinoline Methanol: An Experimental Antimalarial

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

2,4,7-Triamino-6-ortho-substituted Arylpteridines. A New Series of Potent Antimalarial Agents

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Potential antimalarials. 9. Resolution of .alpha.-diheptylaminomethyl-6-bromo-9-phenanthrenemethanol by an unusual method

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

The chemotherapy of rodent malaria, XXV. Antimalarial activity of WR 122,455 (a 9-phenanthrenemethanol) in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

THE USE OF SN-10,275 IN THE PROPHYLAXIS AND TREATMENT OF SPOROZOITE-INDUCED VIV AX MALARIA (CHESSON STRAIN)

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Laboratory evaluation of the photoxic potency of quinolylmethanols

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Chemotherapy of malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Cardiopulmonary effects of antimalarial drugs. II. Phenanthrenemethanols

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Infections with Plasmodium falciparum and Plasmodium vivax in the owl monkey--model systems for basic biological and chemotherapeutic studies

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Preliminary Study of WR 33063 in the Treatment of Falciparum Malaria in Northeast Thailand *

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

The Army Malaria Research Program

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Mefloquine (WR 142,490) in the Treatment of Human Malaria

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Pharmacology of the malaria parasite—A study of dose-response relationships in chloroquine-induced autophagic vacuole formation in Plasmodium berghei

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

Sustained release of an antimalarial drug using a copolymer of glycolic/lactic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2960241-0

7 January 2021

United States Army Medical Research and Development Command

2

Arnold

1973

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

3

Arnold

1973

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

4

Arnold

1973

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

5

Arnold

1973

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

6

Arnold

1974

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

7

Arnold

1974

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

8

Arnold

1975

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

15 April 2023

12

18

204

Caldwell

1976

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

Drug Metabolism and Disposition

15 April 2023

20

6

82

Chung

1978

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

Drug Metabolism and Disposition

15 April 2023

43

4

133

Grindel

1976

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

55

Lee

1967

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

56

Lee

1968

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

57

Lee

1968

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

58

Lee

1968

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

59

Lee

1968

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

60

Lee

1968

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

61

Lee

1970

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

62

Lee

1970

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

63

Lee

1970

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

64

Lee

1971

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

65

Lee

1971

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

66

Lee

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

67

Lee

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

68

Lee

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

69

Lee

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

70

Lee

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

71

Lee

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

72

Lee

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

73

Lee

1973

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

74

Lee

1973

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

75

Lee

1974

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

76

Lee

1974

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

77

Lee

1974

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

78

Lee

1974

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

80

Lee

1976

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

81

Lee

1976

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

82

Lee

1976

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

83

Lee

1976

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

15 April 2023

88

18

171

Minor

1976

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

Drug Metabolism and Disposition

15 April 2023

90

3

198

Mu

1975

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

The chemotherapy of rodent malaria, XXVI. The potential value of WR 122,455 (a 9-phenanthrenemethanol) against drug-resistant malaria parasites

15 April 2023

99

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

The chemotherapy of rodent malaria, XXVII Studies on mefloquine (WR 142,490)

15 April 2023

101

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

107

Powers

1970

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

Evaluation of two phenanthrenemethanols for antimalarial activity in man: WR 122,455 and WR 171,669

15 April 2023

113

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

United States Army Medical Research and Development Command

15 April 2023

120

Schmidt

1974

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

15 April 2023

123

13

269

Smith

1971

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

Toxicology and Applied Pharmacology

15 April 2023

124

19

364

Smith

1971

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

Toxicology and Applied Pharmacology

15 April 2023

125

22

291

Smith

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60241-0

15 April 2023

Identifiers

0 references

1 reference